Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab

Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab

Radiation-induced sarcoma (RIS) has been reported as a late secondary malignancy following radiotherapy for various types of cancer with a median latency of 10 years. We describe an early RIS that developed in an adolescent within three years of treatment (including PD-L1 check-point inhibitor Nivol...

Full description

Bibliographic Details
Main Authors: Lukas Šalaševičius, Goda Elizabeta Vaitkevičienė, Ramunė Pasaulienė, Rosita Kiudelienė, Ernesta Ivanauskaitė-Didžiokienė, Donatas Vajauskas, Nemira Jurkienė, Jelena Rascon
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Medicina
Subjects:
Hodgkin lymphoma
post-radiation sarcoma
Nivolumab
children
obesity
Online Access:https://www.mdpi.com/1010-660X/56/4/155
Description
Summary:Radiation-induced sarcoma (RIS) has been reported as a late secondary malignancy following radiotherapy for various types of cancer with a median latency of 10 years. We describe an early RIS that developed in an adolescent within three years of treatment (including PD-L1 check-point inhibitor Nivolumab) of a relapsed classic Hodgkin lymphoma (HL) and was diagnosed post-mortem. The patient died of the progressive RIS that was misleadingly assumed to be a resistant HL based on the positive PET/CT scan. Repetitive tumor biopsies are warranted in cases of aggressive and multi-drug resistant HL to validate imaging findings, ensure correct diagnosis and avoid overtreatment.
ISSN:1010-660X

Similar Items